Phase 3
N=24
Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%
Androgenetic Alopecia
Bottom Line
View on ClinicalTrials.gov: NCT03753113 ↗Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcome: Primary: Change in Hair Diameter — 57.42; 51.58; 60.92; 51.17 micrometer
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Topical Herbal Solution (Drug); Topical Minoxidil 5% (Drug)
- Age
- Adult · 18+ yrs
- Sex
- Male
- Sponsor
- Farid Masoud
- Primary completion
- Sep 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Hair Diameter |
57.42; 51.58; 60.92; 51.17; 62.67; 50.58 | — |
| SECONDARY Patients Self - Assessment Questionnaire |
1.25; 2.58 | — |
| SECONDARY Adverse Events |
1; 4; 0; 2; 0; 2 | — |
Summary
The purpose of this study is evaluating the efficacy and safety of a topical herbal solution in males for the treatment of Androgenetic alopecia.
Eligibility Criteria
Inclusion Criteria
- Men 18 to 50 years old
- Written consent
- Normal general health status
- Men who have a presentation of androgenetic alopecia (Norwood II - V).
Exclusion Criteria
- Use of any topical product in the target region interfering with the study product in the last three months
- Within the past 6 months receiving of chemotherapy/cytotoxic agents
- Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
- Uncontrolled hypertension
- Any dermatological disorders in the scalp, such as fungal or bacterial infections, eczema, atopic dermatitis, seborrheic dermatitis, psoriasis, sun damage, skin cancer
- Hormonal diseases such as thyroid disorders, diabetes and, ...
- Smokers
- Liver and kidney disease
- History of hair transplants
- History of surgical correction of hair loss on the scalp
- Subject having dyed, bleached hair or, with a permanent wave prior to study start.
- No written consent
Data sourced from ClinicalTrials.gov (NCT03753113). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.